GNRH1 and prostate carcinoma: In 2019, Østergren et al. conducted a study to compare the metabolic effects of two androgen deprivation therapy (ADT) methods for advanced prostate cancer: gonadotropin-releasing hormone (GnRH) agonists and orchiectomy.